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Abstract
Glioblastoma multiforme (GBM) is the most common and malignant form of glioma with high mortality and no cure. Many
human cancers maintain a complex inflammatory program triggering rapid recruitment of inflammatory cells, including
mast cells (MCs), to the tumor site. However, the potential contribution of MCs in glioma has not been addressed previously.
Here we report for the first time that MCs infiltrate KRas+Akt-induced gliomas, using the RCAS/TV-a system, where KRas and
Akt are transduced by RCAS into the brains of neonatal Gtv-a- or Ntv-a transgenic mice lacking Ink4a or Arf. The most
abundant MC infiltration was observed in high-grade gliomas of Arf2/2 mice. MC accumulation could be localized to the
vicinity of glioma-associated vessels but also within the tumor mass. Importantly, proliferating MCs were detected,
suggesting that the MC accumulation was caused by local expansion of the MC population. In line with these findings,
strong expression of stem cell factor (SCF), i.e. the main MC growth factor, was detected, in particular around tumor blood
vessels. Further, glioma cells expressed the MC chemotaxin CXCL12 and MCs expressed the corresponding receptor, i.e.
CXCR4, suggesting that MCs could be attracted to the tumor through the CXCL12/CXCR4 axis. Supporting a role for MCs in
glioma, strong MC infiltration was detected in human glioma, where GBMs contained significantly higher MC numbers than
grade II tumors did. Moreover, human GBMs were positive for CXCL12 and the infiltrating MCs were positive for CXCR4. In
conclusion, we provide the first evidence for a role for MCs in glioma.
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Introduction
Gliomas arethe mostfrequent primarybrain tumorsof adultsthat
are classified into grades I–IV based on malignancy. Glioblastoma
multiforme (GBM) is the most common and malignant type of
glioma that has poor prognosis, with a median survival time of just
over one year [1] and no cure.
Hallmarks of glioma include disruption of the blood brain
barrier (BBB) and aberrant invasiveness. Disruption of the BBB
occurs in high-grade gliomas, is associated with abnormal
neovasculature and extreme vessel leakiness, which promote
expansion of GBM [2]. The process of invasion is an early and
complex feature of glioma cells that is initiated already in low-
grade gliomas and involves, in addition to glioma cell interactions
with extra-cellular matrix (ECM), multiple additional factors
accompanying glioma cell movement [3].
The rate of development and growth of tumors is regulated by
the balance between pro- and anti-tumorigenic signals, produced
either by the tumor cells themselves, or by the surrounding
microenvironment. Local chronic inflammation, at the site of
tumor growth, is a potent cancer promoter and results in induction
of angiogenesis, tissue remodeling and immune modulation. Many
human cancers, including gliomas, instruct and maintain a
complex inflammatory program that, among other effects, triggers
rapid recruitment of inflammatory cells to the tumor site. For
example, immune infiltration of gliomas was recognized as one of
the processes following the development of advanced gliomas, and
it has been demonstrated that gliomas are infiltrated by microglia,
CD4 and CD8 T lymphocytes, and natural killer (NK) cells [4,5].
Generally, there appears to exist a positive correlation between the
extent of immune infiltration and poor clinical outcome. However,
the exact contribution of the immune system in tumorigenesis is
still not clear.
Mast cells (MCs) are crucial players in various inflammatory
conditions, including cancer [6]. The specific role of MCs in
tumorigenesis may vary largely, depending on the type of cancer.
MCs have been identified as an early highly infiltrative cell type in
skin dysplasias [7], breast carcinoma [8], colorectal carcinoma [9],
malignant melanomas [10], and pancreatic islet tumors [11]. A
protumorigenic role for MCs has been indicated in thyroid cancer
[12] and MCs have been associated with poor prognosis in
prostate cancer [13]. Conversely, an association between presence
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25222of MCs and improved prognosis has also been documented [14].
Hence, MC-related inflammatory processes might either facilitate
or hinder cancer, depending on the type of tumor setting. Notably,
previous studies investigating the role of MCs in cancer have been
focused on tumors outside of the central nervous system (CNS).
Here we are for the first time analyzing the potential involvement
of MCs in brain tumors. MCs are known to populate the CNS of
several species, including humans and have been found there from
the time of birth. In the brains of mammals they are concentrated
in the medial habenula (MHb), which is part of the epithalamus
[15].
During the past decade, the RCAS/TV-a mouse model has
become an important system for studying glioma [16]. RCAS/
TV-a allows post-natal gene transfer mediated by oncogene-
carrying RCAS retrovirus into brains of transgene animals
engineered to express the tv-a receptor under the control of cell-
type-specific promoters (e.g. Ntv-a; Gtv-a). In Ntv-a mice, the nestin
promoter directs infection to neural/glial progenitor cells, while in
Gtv-a mice, the glial fibrillary acidic protein (GFAP) promoter
directs infection mainly to astrocytes. The tv-a transgenic mice
have been cross-bred with mice carrying targeted deletions of
tumor suppressor genes (Ink4a2/2; Arf2/2) frequently deleted in
human glioma [17]. Tumors can be induced by RCAS-mediated
transfer of oncogenes, e.g. PDGF, Kras, Akt that closely resembles
the histopathology and genetics of human glioma. Using such
models, key mechanistic insights into gliomagenesis have been
obtained [17,18,19,20]. RCAS/TV-a experimental models have
also been used for pre-clinical testing of immunotherapies [21]. In
the present investigation we have used gliomas generated from
Ntv-a and Gtv-a transgenic mouse lines by transduction of Kras and
Akt [17].
We have investigated whether MCs have a role in glioma and
show for the first time that both mouse and human gliomas
accommodate MCs. Moreover, we present evidence suggesting
that tumor-associated vessels produce SCF that drives MC
proliferation and that MC chemotaxis in gliomas involves
interaction between CXCL12 and CXCR4.
Results
Infiltration of connective tissue type mast cells in mouse
glioma
To address the potential role for MCs in gliomagenesis, we used
archival RCAS/TV-a derived gliomas of various grades and types.
In previous studies it has been shown that the absence of either of
the key tumor suppressors Ink4a or Arf in Ntv-a and Gtv-a transgenic
mice yields tumors upon infection with the combination of RCAS-
KRas + RCAS-Akt. Arf-loss caused increased malignancy of gliomas
compared to Ink4a-loss, indicating a prominent role for Arf in
tumor progression [17]. Tumors were analyzed for the presence of
MCs by performing chloroacetate esterase enzymatic staining,
which detects chymotrypsin-like activity within MC granules. As
shown in Figure 1, MCs were present in gliomas of both Ntv-a and
Gtv-a transgenes, and both in Arf2/2 and Ink42/2 animals.
However, the most profound MC infiltration was seen in high-
grade gliomas, i.e. in Arf2/2 mice, whereas less prominent MC
infiltration was seen in low-grade gliomas, i.e. in Ink4a2/2 mice
(Figure 1A–B). Quantification of these data revealed that in
addition to striking increase of MC numbers in glioma area, there
was also a significant increase in MC numbers within glioma-
associated MHb in Arf knock-out mice (Figure 1C). Hence, MCs
infiltrate gliomas, with the most evident MC infiltration found in
high-grade gliomas in Arf2/2 mice. Therefore, in the subsequent
experiments we have focused on tumors formed in Arf2/2 mice.
There are two main subtypes of MCs in mouse, connective
tissue type MCs (CTMCs) and mucosal type MCs (MMCs), and
these are distinguished by characteristic expression profiles of
various MC-specific proteases [22]. CTMCs express predomi-
nantly chymases of the mouse mast cell protease 4 (mMCP-4) and
mMCP-5 types, tryptases mMCP-6 and mMCP-7, and MC
carboxypeptidase A (MC-CPA), whereas MMCs express the
chymases mMCP-1 and mMCP-2 but no tryptases or MC-CPA.
As shown in Figure 1D, MCs present in tumors of Ntv-a- and Gtv-a
Arf2/2 mice stained positively for both of the CTMC markers,
mMCP-6 and MC-CPA, but were negative for the MMC marker
mMCP-1 (not shown). Hence, MCs in the experimental gliomas
were of the CTMC subtype.
Frequent perivascular localization of mast cells in mouse
gliomas
As shown by co-staining for the endothelial cell marker CD31
and the MC marker mMCP-6, MCs within experimental gliomas
frequently showed a perivascular localization (with an average of
50% for both Ntv-a- and Gtv-a Arf2/2 mice) (Figure 2A), but were
also present within the tumor mass in both Ntv-a- and Gtv-a lines.
SCF is the most important growth factor for MCs in all species
[23]. SCF is an essential chemoattractant for MCs that controls
differentiation of MCs and induces MC proliferation and
degranulation. We reasoned that the massive increase in MC
numbers in the high-grade gliomas, as opposed to normal tissue,
might be a result of glioma-driven SCF expression. We analyzed
the expression of SCF in the mouse gliomas and found
significantly increased expression of SCF in tumor vessels of both
Ntv-a- and Gtv-a Arf2/2 mice (Figure 2B, blue arrow) but also MC
granules were positive (Figure 2B; indicated by red arrows). In
contrast, SCF expression in vessels of non-tumor tissue was poor.
Thus, KRas+Akt-induced experimental gliomagenesis is closely
associated with increased, predominantly vascular expression of
SCF, providing a potential explanation for the increased MC
numbers in the tumor tissues.
Proliferation of mast cells in mouse glioma
The accumulation of MCs in gliomas may be the result of
increased recruitment of blood-borne MC progenitors. An
alternative explanation could be that the increase in MC numbers
is a result of proliferation of local MC populations. To evaluate
this latter possibility we analyzed for the presence of proliferating
MCs, by doing double staining for Ki-67 (a marker for
proliferating cells) and mMCP-6 (a marker of differentiated
MCs). Indeed, we were able to identify proliferating MCs in both
Ntv-a- and Gtv-a Arf2/2 mouse gliomas as compared with non-
tumor tissue (Figure 3A), with an average of 7% and 4% of
proliferative MCs, respectively (Figure 3B). The double positivity
for Ki-67 and mMCP-6 suggested that the gliomas could induce
proliferation of functional MCs. Since no validated markers for
MC progenitors have been established, we were not able to
evaluate the possibility that the gliomas induced proliferation of
local MC progenitors.
Evidence for an active CXCL12/CXCR4 axis in mouse
glioma
The chemokine CXCL12 (also known as stromal cell derived
factor-1 (SDF-1)) is widely expressed in many tissues throughout
development [24] and serves as a powerful chemoattractant for
hematopoietic cells, facilitating their migration through endothe-
lial cell barriers [25]. Moreover, CXCL12 is expressed in a large
number of tumors and injured tissues, and the corresponding
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and metastasis of tumor cells [27]. Since CXCL12 is also known to
act as a chemoattractant for MCs [28], we reasoned that MC
migration into the tumor tissues might be the result of an
interaction between CXCL12 and CXCR4. It has been previously
shown, that CXCL12 was expressed by glioma cells [29,30] and its
expression increased with increasing tumor grade. We analyzed
gliomas for expression of CXCL12 and CXCR4 and found
abundant expression of CXCL12 in both Ntv-a- and Gtv-a Arf2/2
gliomas (Figure 4; left panel) and there was also a clear expression
of CXCR4 in the same samples (Figure 4; middle panel). CXCL12
expression was confined to the tumor stroma and very weak
expression in the surrounding normal tissue could be found. In
agreement with a role of the CXCL12/CXCR4 axis in promoting
MC migration into the tumors, mMCP-6 positive MCs in both
Ntv-a Arf2/2 and Gtv-a Arf2/2 mouse gliomas were frequently
(with an average of 90%) CXCR4 positive (Figure 5A–C).
Interestingly, the staining for mMCP-6 and CXCR4 revealed a
spatial colocalization in MCs, suggesting that part of the CXCR4
pool could be present at the same site as mMCP-6 (secretory
granules), but also that a fraction of the CXCR4 protein is present
at sites distinct from the granules (Figure 5B; right panels).
To elucidate the mechanistic interplay of the receptor-bearing
and ligand-producing cells, we performed an in vitro migration
assay in which bone marrow derived mast cells (BMMCs) were
placed into hanging inserts and were allowed to actively migrate
through a porous membrane towards conditioned medium
acquired after a 72 hour long glioma cell culturing period. A
glioma cell line was established from a KRas+Akt-induced mouse
tumor. Migration of untreated MCs towards glioma cell-
conditioned medium was set to 100% and unconditioned medium
was used as a negative control. Specific blockade of CXCL12
decreased MC migration by circa 32% and 20% as compared to
migration towards glioma cell-conditioned medium or glioma cell-
conditioned medium supplemented with non-specific IgG, respec-
tively (Figure 6A). Similar results were obtained when CXCR4
was specifically blocked on the MC surface and cells were allowed
to migrate towards glioma-conditioned medium (Figure 6B).
Figure 1. Accumulation of MCs in RCAS-KRas+RCAS-Akt induced tumors from Ntv-a Ink4a2/2, Ntv-a Arf2/2, Gtv-a Ink4a2/2 and Gtv-a
Arf2/2 mice. (A) Chloroacetate esterase (CE) and H&E-stained Ntv-a Ink4a2/2 and Ntv-a Arf2/2 tumors. Arrows in left panels indicate MCs. Scale
bar=100 mM. (B) Chloroacetate esterase (CE)- and H&E-stained Gtv-a Ink4a2/2 and Gtv-a Arf2/2 tumors. Arrows indicate MCs. (C) Quantification of
MCs in both non-tumor MHb (MHb, 2 tumor), cancerous MHb (MHb, + tumor) and in the tumor area (tumor) of mouse glioma samples. Ntv-a
Ink4a2/2 (MHb 2 tumor, n=6; MHb + tumor, n=12; tumor, n=12), Ntv-a Arf2/2 (MHb 2 tumor, n=6; MHb + tumor, n=12; tumor, n=12), Gtv-a
Ink4a2/2 (MHb 2 tumor, n=6; MHb + tumor, n=2; tumor, n=2), Gtv-a Arf2/2 (MHb 2 tumor, n=6; MHb + tumor, n=12; tumor, n=12) revealing
statistically significant difference between all compared groups for Arf deficient mice (** p,0.01, *** p,0.001). Error bars show SD. (D)M C
carboxypeptidase A (MC-CPA)- and mMCP-6 positive MCs from the Ntv-a Arf2/2 tumor.
doi:10.1371/journal.pone.0025222.g001
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[29,31], endothelial cells can be an additional source of CXCL12.
We therefore analyzed the gliomas for expression of CXCL12 and
the endothelial cell marker CD31 (Figure 6C). The quantification
revealed that up to 95% of endothelial cells are indeed CXCL12
positive in both Ntv-a Arf2/2 and Gtv-a Arf2/2 mouse gliomas
(Figure 6C). However, only 15% of all CXCL12-positive cells are
endothelial cells. This suggests that glioma cells, in accordance
Figure 2. MC distribution in the mouse RCAS-KRas+RCAS-Akt induced brain tumors. (A) Immunofluorescence staining for endothelial cell
marker CD31 and MC tryptase mMCP-6 in Ntv-a Arf2/2 and Gtv-a Arf2/2 mouse brain tumors revealed perivascular localization of MCs. Lower
panel: quantification of perivascular MCs in mouse brain tumors revealed about 50% in the corresponding objective fields with no difference
between Ntv-a Arf2/2 (n=5) and Gtv-a Arf2/2 (n=5). Error bars show SD. Scale bar=50 mM. (B) Immunohistochemical analysis for SCF expression
revealing marked expression of SCF in the glioma vascular structures in both Ntv-a Arf2/2 and Gtv-a Arf2/2 mice (indicated by blue arrows).
Expression of SCF was also observed in MC granules (indicated by red arrows). Lower panel: quantification of total absolute intensity signal for SCF
revealed statistically significant difference between tumor and nontumor areas of the objective fields in both Ntv-a Arf2/2 and Gtv-a Arf2/2 mouse
brain tumors (* p,0.05). Error bars show SD. Scale bar=50 mM.
doi:10.1371/journal.pone.0025222.g002
Figure 3. Proliferation of MCs in mouse RCAS-KRas+RCAS-Akt induced gliomas. (A) Immunofluorescence co-staining for proliferation
marker Ki-67 and MC tryptase mMCP-6 in mouse brain tumors, revealing proliferation of MCs in both Ntv-a Arf2/2 and Gtv-a Arf2/2 mouse gliomas.
Maximum intensity projection of z-stack confocal images was applied. (B) Quantification of proliferative MCs in both non-tumor MHb (MHb, 2
tumor), cancerous MHb (MHb, + tumor) and in the tumor area (tumor) of mouse glioma samples. The number of Ki-67-positive MCs in the tumor was
significantly higher as compared to both MHb controls, being 7% and 4% in Ntv-a Arf2/2 and Gtv-a Arf2/2 mouse gliomas, respectively. For both
Ntv-a Arf2/2 and Gtv-a Arf2/2 mouse gliomas: MHb 2 tumor, n=6; MHb + tumor, n=6; tumor, n=6; * p,0.05, ** p,0.01. Error bars show SD.
doi:10.1371/journal.pone.0025222.g003
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source of CXCL12 production and hence attract MCs via a
CXCL12/CXCR4 axis.
CXCL12 is a potential chemotaxin for CXCR4-positive
MCs in human GBM
In order to evaluate the potential role of MCs in human
gliomas, we stained human low-grade gliomas (II) and GBMs
(grade IV) for MC tryptase (hTPS). A comparison of the grade II
and grade IV tumors demonstrated a remarkable accumulation of
MCs in the more malignant tumors (GBMs) (n=10) as compared
to grade II tumors (n=8) (Figure 7A).
All GBM patients used in the study had received glucosteroids
prior to and after surgery (Table 1). This anti-inflammatory drug is
known to have an indirect effect on reduction of MC numbers in
vivo [32]. Quantification of positive cells revealed a statistically
significant difference (p,0.001) in MC numbers between low-
grade and high-grade gliomas (Figure 7A), and suggests that MC
accumulation accompanies development of GBM in humans
(Figure 7A). Similar to mouse gliomas, MCs in the human gliomas
showed a predominantly perivascular localization and stained
positive for both CXCL12 and CXCR4 (Figure 7B). Further,
mimicking the situation in the mouse gliomas, tryptase-positive
MCs present in human GBMs were frequently positive for
CXCR4 (Figure 7C).
Discussion
It still remains uncertainwhether inflammationis thecause orthe
result of cancer. Despite numerous studies addressing this issue, the
genuineconnectionsbetweeninflammatory- andtumorcellsarestill
unresolved. Glioma is one of the types of cancer with most
discouraging prognosis, and research on glioma has therefore
expanded dramatically. However, the contribution of inflammation
in gliomagenesis is not fully understood. Previous studies have
implicated various immune cells, such as T cells, microglia and NK
cells, during glioma development. Generally, these types of immune
cells have been suggested to have pro-tumorigenic effects, with their
presence being correlated with increased malignancy grade [4,5].
During the past years, a number of studies showing significant
correlations between MC infiltration and cancer development
have been published [8,11,12,13]. In many cases, the presence of
MCs has been correlated with poor prognosis, but associations of
Figure 4. CXCL12 and CXCR4 expression in mouse RCAS-KRas+RCAS-Akt induced gliomas. Immunofluorescence staining for CXCL12 and
CXCR4 was performed in both Ntv-a Arf2/2 and Gtv-a Arf2/2 mouse gliomas. The quantification of intensity signal for CXCL12 (lower left panel) and
CXCR4 (lower right panel) revealed statistically significant difference between tumor and nontumor areas of the objective fields in both Ntv-a Arf2/2
and Gtv-a Arf2/2 mouse brain tumors (* p,0.05). Error bars show SD. Scale bar=50 mM.
doi:10.1371/journal.pone.0025222.g004
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Thus the prognostic value of MC infiltration into tumors is
controversial, and the exact role of MCs in tumor development
remains elusive. In fact, it cannot be excluded that MCs perform
partly opposing roles in tumor formation/development during
distinct tumor stages, this being in line with the proposed
protective effect of the immune system in early phases of
tumorigenesis while the immune system may enhance tumorigen-
esis at later stages of tumor development [33].
Here we have expanded our understanding of the role of
inflammation in gliomas by showing, for the first time, that MCs
infiltrate mouse and human glioma, and that the extent of MC
infiltration, both in mouse and human gliomas, shows a strong
positive correlation with the malignancy grade of the tumor.
Despite the pre- and post-treatment of GBM patients with
glucosteroids, the difference in MC numbers was significant as
compared to low-grade samples (not receiving the anti-inflamma-
tory drug), and suggests that it could have been even more
pronounced. The mouse studies were performed using the RCAS/
TV-a mouse model system that produces life-like gliomas of
different types and grades. We compared the extent of MC
infiltration in tumors, induced with a combination of two
oncogenes (KRas+Akt) in two different transgenic lines (Ntv-a and
Gtv-a), each carrying a deficiency in either of the tumor suppressors
Ink4a or Arf. We found that the number of MCs in high-grade
tumors generated in Arf-deficient mice was significantly higher
than in low-grade gliomas formed in Ink4a-deficient mice, thus
suggesting that accumulation of MCs accompanies development of
high-grade gliomas. In contrast, the cell-of-origin, i.e. neural/glial
cell progenitors (Ntv-a) or astrocytes (Gtv-a) did not affect the extent
of MC accumulation to any significant extent, indicating that MCs
are accumulated in gliomas regardless of the cellular origin of the
tumor. Notably, the induction of tumors by KRas+Akt in Arf2/2
mice has been shown to generate predominantly GBM-like
gliomas. By using this model, we have been able to get a more
complete understanding of the processes leading to MC infiltration
and distribution during glioma progression, than by mere
examination of human glioma material.
The pronounced accumulation of MCs in the mouse gliomas
suggested that glioma cells produce factors that can stimulate
proliferation of MCs, as well as attracting MCs to migrate into the
tumor. We show that SCF was highly expressed in tumor blood
vessels but not in vessels outside the tumor tissue, and propose that
the accumulation and perivascular localization of MCs in gliomas
is, at least partly, explained by a glioma-driven induction of SCF
expression. This hypothesis is also supported by a previous study,
in which SCF expression was demonstrated in blood vessels of
human glioma [34]. Another striking finding was that MCs
themselves were strongly positive for SCF, arguing that expansion
of the brain tumor-associated MCs may result, at least partly, from
an autocrine loop induced by release of MC-contained SCF,
which subsequently could bind to its receptor (c-kit) on the MC
surface. Binding of SCF to c-kit could then induce MC
proliferation, and, in agreement with this, we observed prolifer-
ation of glioma-associated MCs. Together, these data demonstrate
for the first time that brain tumor-associated MCs contain
endogenous sources of SCF, a finding that is in agreement with
a previous study showing that human skin MCs may contain a
preformed pool of SCF [35].
SCF may, in addition to inducing MC proliferation, also serve
as a MC chemoattractant. However, SCF expression was low
within the tumor mass, and the localization of MCs within the
tumor mass was therefore most likely the result of chemotaxis
induced by factors other than SCF. Taking into account that the
CXCL12/CXCR4 interaction has a pronounced role in develop-
ment of tumor vasculature [36], and that CXCL12 is a known MC
chemotaxin [28], we demonstrated that both mouse and human
gliomas were highly positive for CXCL12. Further, human and
mouse glioma MCs were strongly positive for its cognate receptor
CXCR4, this being in agreement with previous reports showing
the expression of CXCR4 in human glioma [36,37]. In the in vitro
migration assay CXCL12 neutralization in glioma-conditioned
medium led to a significant decrease of MC migration. Similarly,
blocking of its receptor, CXCR4, resulted in reduced migration of
MCs further, strengthening the notion that a CXCL12/CXCR4
axis plays an active role in MC recruitment to the tumor site.
Hence, we propose that the MC accumulation within the gliomas
is, at least partly, explained by a glioma-driven expression of
CXCL12, combined with strong expression of CXCR4 within the
brain tumor MC population.
CXCL12/CXCR4 interactions have been implied in vascular-
ization processes, and it has been demonstrated that CXCL12
signaling is inducible in pathological conditions of the CNS [38]
pointing to a potential role of CXCL12 in pathological formation
of vessels within the brain. Accordingly, it has been suggested that
the CXCL12/CXCR4 axis modulates the formation of new
vessels under certain pathological conditions of the brain [39].
Despite being expressed by glioma cells at a higher level, CXCL12
is additionally expressed by endothelial cells further increasing its
chemotactic potential.
The findings presented here show that MCs are present in
glioma with higher numbers in more malignant tumors proposing
a potential prognostic value for detecting MCs. The result suggests
that MCs contribute to the progression of glioma but the exact
nature of this contribution remains to be elucidated. One favored
possibility would be that MCs promote the tumor angiogenesis in
gliomas, a notion that is well in line with a proposed function of
MCs in various other types of tumor settings [33]. Potentially,
MCs may promote angiogenesis by multiple mechanisms,
including the secretion of angiogenic factors [40] or by the
secretion of MC proteases that may either directly degrade ECM
components or promote ECM degradation by activating other
ECM-degrading proteases such as matrix metalloprotease 9 [41].
There is as yet no cure for high-grade gliomas. Since MCs are
normal cells within the tumor that should be less sensitive to
developing therapy resistance, potential drugs that modulate MC




In the animal studies animals had free access to food and water
and they were housed and treated following the conditions
Figure 5. Co-expression of CXCR4 and mMCP-6 by MCs in mouse RCAS-KRas+RCAS-Akt induced gliomas. (A) Immunofluorescence
staining for CXCR4 and mMCP-6 was performed in both Ntv-a Arf2/2 and Gtv-a Arf2/2 mouse gliomas, demonstrating co-expression of CXCR4 and
mMCP-6. Scale bar=50 mM. (B) Immunofluorescence staining, demonstrated co-localization of CXCR4 and mMCP-6 at the single-cell level in both
Ntv-a Arf2/2 and Gtv-a Arf2/2 mouse gliomas. Maximum intensity projection of z-stack confocal images was applied. Scale bar=20 mM. (C) The
quantification of MCs in mouse brain tumors revealed about 90% to be CXCR4-positive in the corresponding objective fields with no difference
between Ntv-a Arf2/2 (n=5) and Gtv-a Arf2/2 (n=5). Error bars show SD.
doi:10.1371/journal.pone.0025222.g005
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which also approved the experimental protocol (approval C32/3
from 19.03.2003 and C246/10 from 29.09.2010). All patient
samples were obtained following approval of the Ethics Commit-
tee of Uppsala University (Application Dnr Ups 02-330) and the
Ethics Committee of Karolinska Institutet (Application Dnr Ki 02-
254). Patients gave written informed consent for the sample
collection. The study involving human biopsy samples was
conducted in accordance with the Declaration of Helsinki.
Tissue samples
Constructs and mice used in this study have been previously
described [18]. From archival material, a diverse panel of mouse
brain specimens was selected. The panel includes Ntv-a and Gtv-a
strains of Ink4a2/2 and Arf2/2 background. Tumors were
induced by RCAS virus encoding a combination of KRas+Akt [17].
Human tissue samples were obtained from Uppsala Biobank
material. Both high- and low-grade tumors had been graded based
on the WHO classification by experienced neuropathologists.
Mouse glioma cell culture
Mouse glioma cell culture 3074A was established in Gtv-a
Arf2/2 mouse [18]. Glioma was induced by RCAS virus
encoding a combination of KRas+Akt [17].
The injected mouse was euthanized when showing any sign of
sickness, but at the latest at 12 weeks of age. The brain was
collected under aseptic conditions and a coronal section was made
at the injection site and one part was collected and embedded in
paraffin post formalin fixation, whereas the other part was minced
and dissociated for culturing. The mouse cell line was cultured in
Dulbeco’s Modified Eagle’s Medium (DMEM) (Sigma Aldrich,
MO, USA), supplemented with 10% fetal bovine serum (FBS)
(Invitrogen, Carlsbad, CA), 4 mM L-glutamine and 100 units/ml
penicillin and 0.1 mg/ml streptomycin (Sigma Aldrich). The
expression of KRas+Akt in primary glioma cells was confirmed and
corresponding haematoxylin-stained tissue was ranked as grade III
with susceptibility of developing into a grade IV tumor.
BMMC culture
Bone-marrow cells from Gtv-a wt mice were obtained from
femura and tibia by flushing the bones with 2.5 ml of PBS. The
cells were cultured in DMEM, supplemented with 10% heat-
inactivated FBS, 60 mg/ml penicillin, 50 mg/ml streptomycinsul-
fate, 2 mM L-glutamine and 30% WEHI-3B-conditioned media
(which contains IL-3). The cells were kept at a concentration of
0.5–1610
6 cells/ml with weekly changes of medium. All cells were
grown at 37uC with 5% CO2.
In vitro chemotaxis assay
All chemotaxis experiments were carried out in a 24-well
culture plates using hanging inserts with a 5 mm PET membrane
(Millipore (Billerica, MA)) where 10
5 mast cells were placed.
Conditioned medium was obtained from confluent 3074a mouse
glioma cell culture seeded 72 hours prior to the experiment. It was
subsequently added to the lower wells and DMEM supplemented
with 10% FBS, 4 mM L-glutamine, 100 units/ml penicillin and
0.1 mg/ml streptomycin was used as a negative control. For
neutralization experiments, CXCL12 neutralizing antibody
(250 ng/ml, R&D Systems (Abingdon, UK)) was incubated with
the conditioned medium for 30 minutes at room temperature. In
order to block the receptor on MC surface, CXCR4 antibody
(100 mg/ml, R&D Systems) was incubated with MCs for
60 minutes at room temperature. Control samples were incubated
under same conditions with a matching isotype nonspecific
antibody (mouse monoclonal IgG1 and rat monoclonal IgG2B,
respectively, R&D Systems) diluted to the same concentration.
The experiments were performed in triplicate.
Immunohistochemistry and -fluorescence
Formalin-fixed, paraffin-embedded 6 mm thick tissue sections
were fixated onto glass slides. Thereafter, the sections were
deparafinized (in xylene over night, in fresh xylene for 1 h on a
rocking table followed by 265 min incubations in 100% EtOH,
95% EtOH, 80% EtOH, distilled H2O) and subjected to pressure
boiling for antigen retrieval in antigen unmasking solution (Vector
Labs, Burlingame, CA).
Immunohistochemistry was performed using the UltraVision LP
detection System (Thermo Fisher Scientific, CA) in accordance
with the manufacturer’s instructions. Briefly, after antigen retrieval
the slides were washed in PBS-T (containing 0.05% Tween (Sigma
Aldrich, MO, USA)) and incubated with hydrogen peroxidase
block. Ultra V block was subsequently applied. Primary antibody
used included anti-mouse SCF (1:100, Millipore) and anti-human
tryptase (1:200, Santa Cruz (Santa Cruz, CA)), mMCP-6, CPA,
mMCP-1, mMCP-2 (1:200, Antisera raised in rabbit were as
described [42]. They were diluted in 5% normal goat serum
containing PBS-T and incubated over night at 4uC. Primary
antibody diluted in 5% normal goat serum containing PBS-T was
applied over night at 4uC, followed by primary antibody enhancer.
Slides were incubated with HRP polymer and the signal was
visualized using freshly prepared DAB plus chromogen and
substrate mix. Between all the steps described above, the slides
were thoroughly washed in PBS-T. After the final step, the slides
were washed in distilled H2O, counterstained with hematoxylin
and mounted using Immu-mount (Thermo Fisher Scientific, CA).
Pictures were taken using a Leica brightfield microscope.
For immunofluorescence staining, slides were rinsed in PBS,
blocked in 5% milk-containing PBS-Tx (supplemented with 0.2%
Triton-X 100 (Sigma Aldrich, MO)) for 1 hour, followed by over
night incubation (4uC) with the primary antibody diluted in the
blocking solution in accordance with producer’s guidelines. The
following antibodies with the specific dilutions were used: mMCP-
6 (1:200, antiserum raised in rabbit as described previously), anti-
mouse Ki-67 (1:200, DakoCytomation (Glostrup, Denmark), anti-
mouse CXCR4 (1:50, R&D Systems), anti-human CXCR4 (1:200,
Abcam (Cambridge, UK)), anti-mouse CXCL12 (1:60, R&D
Systems), anti-human CXCL12 (1:100, R&D Systems), anti-
Figure 6. Demonstration of MC migration toward glioma-conditioned medium. Co-expression of CXCL12 and CD31 in mouse RCAS-
KRas+RCAS-Akt induced gliomas. (A) Trans-well assay using CXCL12-neutralizing antibodies revealed statistically significant decreased migration of
BMMCs towards glioma-conditioned medium. (B) Trans-well assay using antibodies to block CXCR4 receptor expressed on the BMMC surface
demonstrated statistically significant decrease in BMMC migration towards glioma-conditioned medium. Appropriate isotype controls were used
(* p,0.05, ** p,0.01). (C) Immunofluorescence staining demonstrated co-localization of CXCL12 and CD31 in both Ntv-a Arf2/2 and Gtv-a Arf2/2
mouse gliomas. Image analysis revealed an average of 16% and 14% of total CXCL12-positive cells in Ntv-a Arf2/2 and Gtv-a Arf2/2 mouse gliomas
respectively were co-localized with CD31-positive endothelial cells. However, almost 94% and 82% of total CD31-positive cells in Ntv-a Arf2/2 and
Gtv-a Arf2/2 mouse gliomas correspondingly were co-localized with CXCL12-positive staining. No statistical difference between Ntv-a- and Gtv-a
lines was found. Scale bar=50 mM. Error bars show SD.
doi:10.1371/journal.pone.0025222.g006
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CD31 (1:50, Santa Cruz). The slides were subsequently incubated
with appropriate secondary antibody for up to 1 hour and
mounted in DAPI (1:5000) containing Immu-mount. In between
the incubations, slides were washed in PBS-Tx. All secondary
antibodies were purchased from Invitrogen (Carlsbad, CA) or
Figure 7. MC infiltration of human gliomas. (A) Immunohistochemical analysis of human MC tryptase (hTRS) in human low-grade gliomas
(grade II, n=8) and glioblastomas multiforme (GBM) (grade IV, n=10). Right panel: quantification of MCs. Error bars show SD, *** p,0.001. Scale
bar=50 mM. (B) Immunofluorescence staining for CXCL12 and CXCR4 in human GBMs. Scale bar=50 mM. (C) Immunofluorescence staining for CXCR4
and hTPS in human GBMs displayed co-expression of CXCR4 and hTPS. Scale bar=25 mM. The inset represents a MC with co-localization of CXCR4
and hTPS at the single-cell level where maximum intensity projection of z-stack confocal images was applied.
doi:10.1371/journal.pone.0025222.g007
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using Zeiss 510 META confocal microscope and Zen software
(version 5.0, 2008). Where applicable, maximum intensity
projection was performed on z-stack images.
Chloroacetate esterase staining was performed as described
previously [43].
The quantification of Ki-67 positive MCs was determined from
four representative tumors each from Ntv-a Arf2/2 and Gtv-a
Arf2/2 mice. The percentage of Ki-67-positive nuclei out of 100
randomly selected MCs was calculated.
The quantification of all images was performed by ImageJ
software.
The number of MCs per square millimeter was counted in
MHb in non-tumor, MHb of tumor-contained sample and in
tumor itself of mouse tissues from different genetic backgrounds.
The number of MCs in human tumor samples was counted per
square millimeter.
Statistical analysis
Where applicable, quantified data are presented as mean 6 SD.
To estimate statistical significance, Student’s unpaired two-tailed t-
test was used.
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